Evidence map›Paper›PMID 39030240›Full record

ArticleScientific reports2024

Automated PD-L1 status prediction in lung cancer with multi-modal PET/CT fusion.

Ronrick Da-Ano, Gustavo Andrade-Miranda, Olena Tankyevych, Dimitris Visvikis, Pierre-Henri Conze, Catherine Cheze Le Rest

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ronrick Da-AnoLaTIM, UMR 1101, Inserm, University of Brest, Brest, France.
Gustavo Andrade-Miranda *LaTIM, UMR 1101, Inserm, University of Brest, Brest, France.
Olena TankyevychLaTIM, UMR 1101, Inserm, University of Brest, Brest, France.
Dimitris VisvikisLaTIM, UMR 1101, Inserm, University of Brest, Brest, France. dimitris@univ-brest.fr.
Pierre-Henri Conze *LaTIM, UMR 1101, Inserm, University of Brest, Brest, France.
Catherine Cheze Le Rest *LaTIM, UMR 1101, Inserm, University of Brest, Brest, France.

Funding

This work was partly funded by the ERA-Net CHIST-ERA grant [CHIST-ERA-19-XAI-007] long term challenges in ICT project INFORM 93603
6 · The paper itself

Abstract

Programmed death-ligand 1 (PD-L1) expressions play a crucial role in guiding therapeutic interventions such as the use of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) in lung cancer. Conventional determination of PD-L1 status includes careful surgical or biopsied tumor specimens. These specimens are gathered through invasive procedures, representing a risk of difficulties and potential challenges in getting reliable and representative tissue samples. Using a single center cohort of 189 patients, our objective was to evaluate various fusion methods that used non-invasive computed tomography (CT) and

Indexed as

B7-H1 AntigenCarcinoma, Non-Small-Cell LungLung NeoplasmsPositron Emission Tomography Computed TomographyAdultAgedAged, 80 and overDeep LearningFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedROC CurveTomography, X-Ray ComputedB7-H1 AntigenCD274 protein, humanFluorodeoxyglucose F18Deep learningImmunotherapy responseMedical imagingMulti-modal fusion

Identifiers

PMID39030240
PMCPMC11271510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.